In its written testimony, NORML Deputy Director Paul Armentano encourages the agency to act expeditiously to clarify confusion among both consumers and regulators with regard to the legality of specific CBD products. It further recommends that the FDA provide regulatory guidelines governing product manufacturing, standardization, and quality.
After decades of hard work by dedicated volunteers and activists from coast-to-coast that mission is one step closer to fruition following the passage of the Cannabis Regulation and Tax Act (HB1438-SFA2) by the Illinois Senate.
Manufacturing and possessing concentrated forms of cannabis are legally protected activities under the state’s medical cannabis access law, according to a unanimous decision issued today by the Arizona Supreme Court. The decision reverses a 2018 ruling by the Arizona Court of Appeals.